A case of metachronous peripheral T‐Cell non‐Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin | Zendy

Meconi Federico | Zendy; Provenzano Ida | Zendy; Nasso Daniela | Zendy; Mariotti Benedetta | Zendy; Pupo Livio | Zendy; Secchi Roberto | Zendy; Cerretti Raffaella | Zendy; Lucia Anemona | Zendy; Arcese William | Zendy; Cantonetti Maria | Zendy

Open Access

A case of metachronous peripheral T‐Cell non‐Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin

Author(s) -

Meconi Federico,

Provenzano Ida,

Nasso Daniela,

Mariotti Benedetta,

Pupo Livio,

Secchi Roberto,

Cerretti Raffaella,

Lucia Anemona,

Arcese William,

Cantonetti Maria

Publication year - 2020

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.2898

Subject(s) - brentuximab vedotin , medicine , abvd , lymphoma , hodgkin lymphoma , oncology , disease , chemotherapy , vinblastine , hodgkin's lymphoma , vincristine , cyclophosphamide

Occasionally, non‐Hodgkin lymphomas (NHL) occur simultaneously or subsequently to Hodgkin disease. We report on a case of a woman with Hodgkin lymphoma treated with ABVD, who developed 4 years later T‐cell NHL with both nodal and extranodal involvement. Brentuximab vedotin could be an effective choice in treating metachronous T‐cell NHL.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research